Krystal Biotech Inc. (NASDAQ: KRYS) saw its stock surge 5.11% in pre-market trading on Monday following the release of its impressive second-quarter 2025 financial results. The biotechnology company reported earnings of $1.29 per share, surpassing analyst estimates of $1.17, and posted quarterly sales of $96.042 million, beating expectations of $94.254 million.
The strong performance was primarily driven by robust sales of VYJUVEK, Krystal Biotech's gene therapy for dystrophic epidermolysis bullosa (DEB). The company reported a 37% year-over-year increase in product revenue, reaching $96 million for the quarter. Additionally, Krystal Biotech announced the approval of VYJUVEK in Japan, marking a significant milestone in its global expansion efforts.
Investors are also optimistic about Krystal Biotech's future prospects, with the company on track to launch VYJUVEK in Japan by the end of 2025 and in Germany in the third quarter of 2025. The strong financial results, coupled with the positive outlook for international expansion, have contributed to the pre-market stock price surge as traders anticipate continued growth for the company.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.